About Biotheranostics
Biotheranostics is a Healthcare company based in San Diego (United States) founded in 2008, and was acquired by Hologic in January 2021. Molecular diagnostics tests for cancer patients are developed and commercialized. Biotheranostics has raised $32 million across 1 funding round from investors including Hologic, MVM Partners and Canepa Healthcare. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is bioTheranostics, Inc. Its competitors include DermTech, NeuMoDx and Kryptos Biotechnologies; 3 of its 3 listed competitors have raised funding.
Company details
BioTheranostics was founded in 2008 and is based in San Diego, United States. Operations focus on the biotechnology sector, where proprietary molecular-based diagnostic, prognostic, and predictive tests are developed and commercialized for cancer treatment guidance. Key offerings include the Breast Cancer Index for decisions on extended endocrine therapy in estrogen receptor-positive breast cancer, and Cancer Type ID for molecular diagnosis and biomarker analysis in metastatic cases.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website biotheranostics.com
- Social LinkedIn
- Acquired by Hologic (Jan 2021)
- Legal Name Biotheranostics, Inc.
Funding Insights of Biotheranostics
Biotheranostics has successfully raised a total of $32M through 1 strategic funding round. The most recent funding activity was a Series A round of $32 million completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $32M
- Total Rounds 1
- Last Round Series A — $32M
- First Round $32M
(Jan 2016)
- Investors Count 3
All 1 funding rounds of Biotheranostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2016 | $32M | Series A | – | MVM |
4 investors in total: 4 institutional.
Investors in Biotheranostics
Biotheranostics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Hologic, MVM Partners and Canepa Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| canepahealthcare.com | ||||
Investments are focused on tech and life sciences startups. | healthquestcapital.com | Belmont, United States | ||
Private equity investments in healthcare companies are managed. | 1997 | mvm.com | London, United Kingdom | |
Diagnostic and surgical products for women's healthcare are provided. | 1985 | hologic.com | Marlborough, United States |
Investor details for Biotheranostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biotheranostics
36 people are tracked at Biotheranostics (10 in leadership, 26 in team).
| Name | Role | Group |
|---|---|---|
Debbie Ledet | VP of Market Access | Leadership |
Bill Zondler | Chief Information Officer | Leadership |
Kevin R. Thornal | Acting CEO | Leadership |
Debra Hadley | VP, Laboratory Operations | Leadership |
Mark Erlander | Chief Scientific Officer | Leadership |
Jennifer Person, DBA | Director, Key Accounts | Leadership |
Stephen Reynolds | Sr. Director of Reimbursement / Revenue Cycle Management | Leadership |
Diane Lincoln | Human Resources Director | Leadership |
Miriam J. Bloch | Laboratory Director | Leadership |
Dennis Hallissey | Director of National Accounts & Strategic Alliances | Leadership |
Ron Hill | Key Account Manager - Great Lakes | Team |
Tessa Abney, M.B.A | Oncology Account Executive | Team |
Tom Boutelle | Regional Account Manager | Team |
Tyra Darling | Key Account Manager | Team |
Jerry L. | Client Services Associate | Team |
Juli McCauley | Account Manager | Team |
BRIAN SEBRELL | Regional Account Manager | Team |
Karla Kelly | General Counsel | Team |
Troy Hein | Clinical Laboratory Scientist | Team |
Jessica Templer | Lead Clinical Laboratory Scientist | Team |
16 more people are available in the full profile.
Complete people profiles for Biotheranostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Biotheranostics
3 dated milestones of Biotheranostics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Biotheranostics is founded.
- Funding First funding round of $32.0M.
- Exit Acquired by Hologic.
Competitors of Biotheranostics
Biotheranostics has 3 listed competitors in our database, 3 of them funded. They include DermTech, NeuMoDx and Kryptos Biotechnologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dermtech.com | 1996 | San Diego, United States | $24.37M | 259 | Adhesive patch biopsies for skin cancer detection are provided. | |
| neumodx.com | 2012 | Ann Arbor, United States | $66.04M | 125 | Developer of a platform for low cost molecular testing | |
| kryptosbio.com | 2017 | Hayward, United States | $12.7M | Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology. |
Detailed competitors of Biotheranostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Biotheranostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biotheranostics
Complete news archive for Biotheranostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biotheranostics
Biotheranostics was founded in 2008 and raised its 1st funding round 8 years after it was founded.
Biotheranostics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Biotheranostics is a funded company, having raised a total of $32M across 1 funding round to date. The company's 1st funding round was a Series A of $32M, raised on Jan 2016.
BioTheranostics was founded in 2008 and is based in San Diego, United States. Operations focus on the biotechnology sector, where proprietary molecular-based diagnostic, prognostic, and predictive tests are developed and commercialized for cancer treatment guidance. Key offerings include the Breast Cancer Index for decisions on extended endocrine therapy in estrogen receptor-positive breast cancer, and Cancer Type ID for molecular diagnosis and biomarker analysis in metastatic cases.
Biotheranostics's top competitors include DermTech, NeuMoDx and Kryptos Biotechnologies.
Biotheranostics has 4 investors. Key investors include Hologic, MVM Partners, Canepa Healthcare, and Health Quest Capital.
Biotheranostics operates through Biotheranostics, Inc..
Yes. Biotheranostics was acquired by Hologic in January 2021.